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Abstract. Compared with therapeutics, diagnostic devices account for a rela-
tively small proportion of healthcare expenditure (less than 10%) and yet timely 
diagnosis as well as continuous monitoring of molecular markers can have a 
major impact on disease outcomes. In particular point of care (or near patient) 
tests can empower individuals to become active participants in the management 
of their conditions, giving them and their medical support greater insight into 
both their conditions and their response to treatment. In an extension of the 
point of care paradigm, continuous monitors of biomarkers and/or therapeutics 
allow high frequency data to be gathered and patterns of variation to be ana-
lyzed in ways that are not possible with infrequent and sporadic testing. The 
advent of novel materials, fabrication methods and data analysis have opened 
the way to new devices, assay formats and molecular targets. In this paper we 
will discuss some aspects of our work in this area with a particular focus on mi-
croneedles for continuous, minimally invasive sensing and the use of nucleic 
acid aptamers in both electrochemical and lateral flow assays. 
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1 Microneedle Sensor Arrays 
Continuous measurement of physiological parameters such as blood pressure, heart 
rate, electrophysiological patterns (electrocardiograms, electroencephalograms), and 
respiration rate are very familiar procedures whether in hospital or, increasingly at 
home. However, as a general observation this approach has not been applied to the 
measurement of molecular parameters (biomarker and drugs). The only significant 
exception is in continuous glucose monitoring (CGM) in Type 1 diabetes and even 
here only a small proportion of individuals with Type 1 diabetes regularly use CGM 
devices. There are several well documented reasons for this including cost, discom-
fort, inconvenience and concerns over reliability. Typically, such CGM is performed 
with a subcutaneously implanted needle modified to generate a glucose dependent 
current when an electrical potential is applied. Over the past several years we have 
taken a different approach to the design and fabrication of continuous sensing devices 
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that we believe overcome many of the limitation of current implanted sensors and 
allow a straightforward extension to continuous monitoring of many other molecular 
species. These microneedle sensor arrays are fabricated by low cost, scalable and 
flexible methods, reside in the dermal interstitial compartment, less than 1mm below 
the surface of the skin, whose fluid (interstitial fluid or ISF) is very close in composi-
tion to serum. This compartment sits above the capillary bed and nerve endings and so 
the microneedles cause neither pain nor bleeding upon insertion. The microneedles 
are shown in Figure 1 and are typically configured as four separate arrays, each array 
comprising 16 electrically contiguous solid microneedles. This format offers a large 
sensing area whilst resulting in no adverse tissue response (inflammation or irritation) 
or collagen capsule formation. 
The base structures are made in polycarbonate by injection moulding and then 
metallized with gold, silver or platinum. Finally, they are functionalized with the rele-
vant sensing chemistries. A complete set of protocols are described in our recent 
Methods in Enzymology chapter [1] and here the use of the devices in continuous 
amperometric and potentiometric sensing will be described. Both these sensing mo-
dalities are well established and have been used with a range of molecular recognition 
chemistries, in the case of amperometric sensors through oxidation or reduction gen-
erating an electrical current and in the case of potentiometric sensors through reac-
tions generating an electrical potential via a local ion flux (most commonly of pro-
tons). 
1.1 Amperometric Sensing 
Many different substrate oxidizing enzymes are known, but one of the earliest and 
still a widely used example is glucose oxidase from Aspergillus niger which catalyses 




The reaction is characteristic of the class of enzymes that utilize oxygen as the elec-
tron acceptor and reduce it to hydrogen peroxide. This product is then reoxidised at a 
positive potential producing a glucose dependent current. The high turnover number, 
robustness, low cost and specificity for glucose, when linked to the importance of 
glucose measurements in the management of diabetes has made it the major applica-
tion for microneedle sensors of many different designs [2]. In our current design the 
enzyme is entrapped in a polyphenol coating which provides sufficient mechanical 
robustness to survive skin insertion.  We have recently published data from 24-hour 
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monitoring of 5 study participants with Type 1 diabetes [3]. In this case the calibra-
tion of the sensor was based on a single point at the start of the monitoring period 
with no further recalibration. Although glucose has been the most intensively studied 
metabolite in ISF with microneedles, others are both tractable and relevant. Perhaps 
the example of lactate is a good one. Like glucose there is an accessible lactate oxi-
dase and continuous monitoring of lactate has applications in both sports performance 
and in the management of sepsis. 
 
1.2 Potentiometric Sensing 
Classically, potentiometric sensors are based on establishing a potential difference 
across an ion selective membrane due to differences in concentration between the two 
compartments separated by the membrane. More recent developments have replaced 
the two-compartment/membrane configuration by solid-state ion sensing electrodes 
(ISE’s) that offer greater robustness and more straightforward fabrication procedures. 
Miller and colleagues have demonstrated the combination of a solid-state potassium 
ISE with hollow microneedles to produce a transdermal potassium sensor [4]. 
Enzyme linked ISE’s have typically linked hydrolytic enzymes to pH sensors and we 
have recently demonstrated microneedle sensing of penicillin with an iridium oxide 




This device could have particular utility in enabling dynamic dosing of antibiotics 
based upon continuous monitoring and a feedback loop [6]. 
 
2 Beyond Enzyme Sensing-Aptamers 
2.1 Affinity Sensing. 
Enzymes exhibit the dual properties of molecular recognition and catalysis, trans-
forming the target analyte and in the process generating a detectable product (hydro-
gen peroxide and protons in the above examples. Affinity reagents simply bind with 
the requisite specificity and affinity to the target analyte and that process then needs 
to be coupled to signal generation. There are many possible affinity reagents and sig-
nal generation schemes, in respect of compatibility with microneedle sensors we have 
chosen redox labelled nucleic acid aptamers as the basis for sensing target molecules 
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that are not amenable to enzymatic sensing. This group comprises protein biomarkers 
and drug molecules amongst others and offers the opportunity to move the single 
measurement, point of care paradigm to continuous monitoring. 
If the application of microneedle sensor arrays is to be of use here, then the target 
analytes should be present in the dermal ISF and studies over the past few years have 
shown that this is indeed the case for both proteins [7] and therapeutic drugs [8]. 
Nucleic acid aptamers are short single stranded DNA or RNA sequences selected 
to bind target molecules with good affinity and specificity. The selection typically 
uses the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) to 
identify binding sequences in a large (1014) pool of random sequences [9]. Once 
known the DNA sequence can be synthesized and modified, for example with a redox 
active group, such that analyte binding brings about a structure switch (Figure 1). This 
alters the distance between the redox group and the electrode surface and so changes 




Fig. 1. Electrochemical transduction of structure switching in an aptamer. MB is the redox 
group methylene blue and k’CT is the charge transfer rate constant 
References  
1. A.E.G. Cass and S. Sharma, “Microneedle Enzyme Sensor Arrays for Continuous In Vivo 
Monitoring.,” Meth. Enzymol., vol. 589, pp. 413–427, 2017. 
2. A. El-Laboudi, N. S. Oliver, A. Cass, and D. Johnston, “Use of microneedle array devices 
for continuous glucose monitoring: a review.,” Diabetes Technol. Ther., vol. 15, no. 1, pp. 101–
115,. 2013. 
5 
3. S. Sharma, A. El-Laboudi, M. Reddy, N. Jugnee, S. Sivasubramaniyam, M. El Sharkawy, P. 
Georgiou, D. Johnston, N. Oliver, and A. E. G. Cass, “A pilot study in humans of microneedle 
sensor arrays for continuous glucose monitoring,” Anal. Methods, vol. 10, no. 18, pp. 2088–
2095, 2018. 
4. P. R. Miller, X. Xiao, I. Brener, D. B. Burckel, R. Narayan, and R. Polsky, “Microneedle-
based transdermal sensor for on-chip potentiometric determination of K(+),” Adv Healthc Ma-
ter, vol. 3, no. 6, pp. 876–881,. 2014. 
5. T. M. Rawson, S. Sharma, P. Georgiou, A. Holmes, A. Cass, and D. O'Hare, “Towards a 
minimally invasive device for beta-lactam monitoring in humans,” Electrochem Commun, vol. 
82, pp. 1–5, 2017. 
6. T. M. Rawson, D. O’Hare, P. Herrero, S. Sharma, L. S. P. Moore, E. de Barra, J. A. Roberts, 
A. C. Gordon, W. Hope, P. Georgiou, A. E. G. Cass, and A. H. Holmes, “Delivering precision 
antimicrobial therapy through closed-loop control systems,” Journal of Antimicrobial Chemo-
therapy, pp. 1–9. 2017. 
7. B. Q. Tran, P. R. Miller, R. M. Taylor, G. Boyd, P. M. Mach, C. N. Rosenzweig, J. T. Baca, 
R. Polsky, and T. Glaros, “Proteomic Characterization of Dermal Interstitial Fluid Extracted 
Using a Novel Microneedle-Assisted Technique.,” J. Proteome Res., vol. 17, no. 1, pp. 479–
485, 2017. 
8. T. K. L. Kiang, S. A. Ranamukhaarachchi, and M. H. H. Ensom, “Revolutionizing Therapeu-
tic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology.,” Phar-
maceutics, vol. 9, no. 4, 2017. 
9. M. Famulok and G. Mayer, “Aptamers and SELEX in Chemistry & Biology,” Chem Biol, 
vol. 21, no. 9, pp. 1055–1058, 2014. 
10. N. Arroyo-Currás, P. Dauphin-Ducharme, G. Ortega, K. L. Ploense, T. E. Kippin, and K. 
W. Plaxco, “Subsecond-Resolved Molecular Measurements in the Living Body Using Chrono-
amperometrically Interrogated Aptamer-Based Sensors.,” ACS Sens, vol. 3, no. 2, pp. 360–366. 
2018. 
